Y Intercept Hong Kong Ltd Invests $513,000 in Pediatrix Medical Group, Inc. $MD

Y Intercept Hong Kong Ltd bought a new position in Pediatrix Medical Group, Inc. (NYSE:MD) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 30,620 shares of the company’s stock, valued at approximately $513,000.

A number of other large investors also recently bought and sold shares of MD. Teacher Retirement System of Texas grew its stake in shares of Pediatrix Medical Group by 58.8% in the third quarter. Teacher Retirement System of Texas now owns 244,269 shares of the company’s stock worth $4,092,000 after acquiring an additional 90,413 shares during the last quarter. Bailard Inc. bought a new position in Pediatrix Medical Group in the 3rd quarter worth about $707,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Pediatrix Medical Group by 18.4% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 28,893 shares of the company’s stock worth $484,000 after purchasing an additional 4,487 shares in the last quarter. Seizert Capital Partners LLC purchased a new stake in Pediatrix Medical Group during the 3rd quarter valued at about $192,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Pediatrix Medical Group during the 3rd quarter valued at about $192,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Trading Down 2.4%

Shares of MD stock opened at $20.92 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 1.83. The stock has a fifty day simple moving average of $22.08 and a two-hundred day simple moving average of $18.89. The firm has a market capitalization of $1.80 billion, a PE ratio of 11.01 and a beta of 0.76. Pediatrix Medical Group, Inc. has a 52-week low of $11.84 and a 52-week high of $24.99.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.21. The firm had revenue of $492.88 million for the quarter, compared to analysts’ expectations of $476.45 million. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The company’s revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.44 earnings per share. On average, analysts predict that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Insider Activity at Pediatrix Medical Group

In related news, CEO Mark S. Ordan sold 23,000 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the sale, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at $6,785,860.05. This represents a 7.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Laura A. Linynsky sold 10,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $21.65, for a total value of $216,500.00. Following the completion of the sale, the director owned 32,232 shares in the company, valued at approximately $697,822.80. The trade was a 23.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 43,478 shares of company stock valued at $972,924. 0.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on MD shares. Zacks Research cut Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 23rd. UBS Group lifted their price objective on Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Monday, December 29th. Finally, Truist Financial raised their price target on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a report on Monday, November 10th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Pediatrix Medical Group has an average rating of “Hold” and an average target price of $21.00.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.